EKSO Share Price Performance
US$10.69
3.96 (58.72%)
12.5% overvalued intrinsic discount
US$9.50
Fair Value
Price US$10.69
AnalystConsensusTarget US$9.50
AnalystHighTarget US$9.50
AnalystLowTarget US$6.00
Fair ValueUS$9.50
Share Pricen/a
Ekso Bionics Holdings, Inc. Stock Price
- 3 Narratives written by author
- 0 Comments on narratives written by author
- 16 Fair Values set on narratives written by author
EKSO Community Narratives
AN
Fair Value US$9.5 12.5% overvalued intrinsic discount
Advanced Exoskeleton Devices Will Broaden Rehabilitation Market Access
1users have liked this narrative
0users have commented on this narrative
11users have followed this narrative
AN
Fair Value US$9.5 12.5% overvalued intrinsic discount
Rising Healthcare Spending And Aging Populations Will Expand Rehab Robotics
0users have liked this narrative
0users have commented on this narrative
1users have followed this narrative
AN
Fair Value US$6 78.2% overvalued intrinsic discount
Enterprise Order Delays Will Weaken Performance But Spark Opportunity
0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
Advanced Exoskeleton Devices Will Broaden Rehabilitation Market Access
Key Takeaways Accelerated adoption and revenue growth are expected from improved reimbursement, regulatory changes, and expanded distribution partnerships. Ongoing AI-driven innovation and recovery of delayed sales position Ekso Bionics for enhanced margins and future earnings stability.Read more
95
users have viewed this narrative1users have liked this narrative
0users have commented on this narrative
11users have followed this narrative
AN
US$9.5
12.5% overvalued intrinsic discount
Fair Value
Profit Margin
3.62%
Future PE
43.16x
Price in 2029
US$10.94
Enterprise Order Delays Will Weaken Performance But Spark Opportunity
Key Takeaways Regulatory changes and demographic trends support long-term demand, but unpredictable reimbursement and healthcare funding limit near-term revenue growth and cash flow stability. Product and partnership expansion offers diversification, though dependence on delayed enterprise sales and high R&D costs could defer profitability.Read more
5
users have viewed this narrative0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
AN
US$6
78.2% overvalued intrinsic discount
Fair Value
Profit Margin
12.91%
Future PE
6.05x
Price in 2028
US$7.13
Rising Healthcare Spending And Aging Populations Will Expand Rehab Robotics
Key Takeaways Accelerated personal exoskeleton adoption, strategic partnerships, and ecosystem initiatives position the company for rapid market penetration and substantial revenue growth beyond conservative forecasts. Integration of proprietary AI technology and expansion into multiple high-demand segments create strong competitive advantages, premium pricing potential, and long-term margin expansion.Read more
22
users have viewed this narrative0users have liked this narrative
0users have commented on this narrative
1users have followed this narrative
AN
US$9.5
12.5% overvalued intrinsic discount
Fair Value
Profit Margin
12.32%
Future PE
10.94x
Price in 2028
US$11.38
Trending Discussion
Recently Updated Narratives
AN
EKSO: Reverse Merger Uncertainty Will Drive Bearish Long Term Outlook
Fair Value: US$9.5 12.5% overvalued intrinsic discount
11 followersusers have followed this narrative
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
AN
EKSO: Q3 Sales Momentum Is Expected To Drive Shares Higher
Fair Value: US$6 78.2% overvalued intrinsic discount
0 followersusers have followed this narrative
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
AN
Rising Healthcare Spending And Aging Populations Will Expand Rehab Robotics
Fair Value: US$9.5 12.5% overvalued intrinsic discount
1 followerusers have followed this narrative
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
Snowflake Analysis
Ekso Bionics Holdings, Inc. Key Details
Last Reported Earnings
Dec 31, 2025
Next Reporting Earnings
n/a
- -3.35
- 53.48%
- -93.14%
- 44.9%
About EKSO
- Founded
- 2005
- Employees
- 53
- CEO
- WebsiteView website
Ekso Bionics Holdings, Inc. designs, develops, distributes, and commercializes exoskeleton products in the Americas, Europe, the Middle East, Africa, the Asia Pacific, and internationally. The company provides EksoNR, a wearable robotic exoskeleton; Ekso Indego Therapy, a powered exoskeleton; Ekso Indego Personal, a powered lower limb orthosis; and Ekso EVO, a wearable upper body exoskeleton. It also develops Ekso Nomad, a power Knee Ankle Foot Orthosis or KAFO; and MediTouch BalanceTutor rehabilitation system, a multidirectional perturbation treadmill outfitted. Ekso Bionics Holdings, Inc. was founded in 2005 and is headquartered in San Rafael, California.
